Form 10 Explorer
10-K
Annual Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Dec 31, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
36 line items · 2 periods
XBRL
ItemDec 31, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
1,701,0005,439,000
Cash and Cash Equivalents
2,276,0007,631,000
Fair Value, Inputs, Level 1
2,276,0007,631,000
Accounts Receivable
1,184,000
Other Non-Operating Current Assets
199,000302,000
Total current assets
4,176,00014,556,000
Property, Plant and Equipment
108,000127,000
Operating Lease Right-of-Use Asset
618,000697,000
Intangible Assets
2,594,0002,313,000
Patents
2,495,0002,197,000
Trademarks
99,000116,000
Other Non-Operating Non-Current Assets
1,112,0001,688,000
Total assets
8,608,00019,381,000
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts Payable
6,383,0006,443,000
Other Current Liabilities
606,0001,986,000
Operating Lease Liability, Current
239,000223,000
Short-Term Debt
2,307,000
Total current liabilities
9,535,0008,652,000
Long-term liability:
Operating Lease Liability, Non-Current
395,000495,000
Total liabilities
9,930,0009,147,000
Stockholders’ (deficit) equity:
Series B Convertible Preferred Stock
689,000
Total Stockholders' Equity
66,00049,000
Total Stockholders' Equity
425,440,000419,004,000
Total Stockholders' Equity
(426,828,000)(409,508,000)
Total stockholders’ (deficit) equity
(1,322,000)10,234,000
Series B Preferred Stock - Preferred Stock
689,000
Common Stock
66,00049,000
Additional Paid-in Capital
425,440,000419,004,000
Retained Earnings
(426,828,000)(409,508,000)
Total liabilities and stockholders’ (deficit) equity
8,608,00019,381,000